Holen Sie sich die Stockscreener-App
4.47
6.68%
0.28
Schlusskurs vom Vortag:
$4.19
Offen:
$4.19
24-Stunden-Volumen:
574.95K
Relative Volume:
2.50
Marktkapitalisierung:
$208.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-293.42M
KGV:
-0.1668
EPS:
-26.8031
Netto-Cashflow:
$-13.51M
1W Leistung:
-3.25%
1M Leistung:
-5.70%
6M Leistung:
+15.50%
1J Leistung:
+146.96%
1-Tages-Spanne:
$4.06
$4.645
1-Wochen-Bereich:
$4.06
$4.75
52-Wochen-Spanne:
$1.566
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.47 | 208.25M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citizens | Mkt Outperform |
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Minerva Neurosciences Inc (NERV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Institutional Confidence - TradingKey
Minerva Neurosciences Inc (NERV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Minerva Neurosciences (NERV) Holds Near Support After Modest Decline: Key Levels in FocusMutual Fund Flow - newsline.com
Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800 - Stock Titan
Minerva Neurosciences (NERV) CEO granted 1.69M stock options at $4.68 strike - Stock Titan
Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68 - Stock Titan
Minerva Neurosciences (NERV) director receives stock options for 50,000 shares - Stock Titan
Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading - Stock Titan
Minerva Neurosciences director granted 50,000 options | NERV Insider Trading - Stock Titan
Minerva Neurosciences (NERV) awards 50,000 stock options to director - Stock Titan
Minerva Neurosciences (NERV) loses 37.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Minerva Neurosciences Inc Q1 2026 Earnings: EPS Misses Estimates, No Revenue ReportedAnnual Report - newsline.com
NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027 - TradingView
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting - TipRanks
Minerva Neurosciences (NERV) holders approve officer shield, drop forum clause - Stock Titan
NERV Q1 2026 Earnings: Wider-than-Expected Loss Highlights Ongoing Development CostsHealthcare Earnings Report - newsline.com
Minerva Neurosciences Establishes Scientific Advisory Board - GlobeNewswire
Minerva Neurosciences (NERV) Holds Near Support After Slight Decline: Key Levels to WatchSMA Signal - thelegaladvocate.com
Minerva Neurosciences Announces Sales Agreement with Leerink Partners for Common Stock Offering (Form 8-K Filing) - Minichart
Minerva Neurosciences (NERV) Edges Lower Near Support Level Amid Quiet TradingOBV Breakout - newsline.com
Minerva Neurosciences Launches ATM Offering to Fund Trial - TipRanks
Minerva Neurosciencesto offer and sell up to $75 million in common stock through Leerink Partners - marketscreener.com
Minerva Neurosciences (NERV) adds $75M ATM program and lengthens key Phase 3 C19 trial - Stock Titan
Minerva Neurosciences (NASDAQ: NERV) launches $75M at‑the‑market stock program - Stock Titan
Minerva Neurosciences Inc (NERV) Q1 2026 Earnings: Wider Loss Highlights Ongoing Pre-Revenue Development StageDownward Estimate Revision - Newser
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Challenges - Newser
All you need to know about Minerva Neurosciences (NERV) rating upgrade to buy - MSN
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Street Estimates, Stock Gains on Pipeline OptimismPost-Earnings Drift - Newser
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - Yahoo Finance
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4 - Stock Titan
Minerva Neurosciences (NERV) Slides -5.22% as Selling Pressure Mounts 2026-05-15Popular Market Picks - Newser
Janus Henderson (NERV) reports 4.3M shares, 9.9% stake disclosed - Stock Titan
Balyasny group (NASDAQ: NERV) discloses a 9.99% stake of 4.32M shares - Stock Titan
TradingKey - TradingKey
Minerva Neurosciences (NERV) Slips -0.90%, Testing $5.22 Support 2026-05-14Dip Buy Trade - The Legal Advocate
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Raises Target Price to $7 - Moomoo
8-K: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updatesmoomoo - Moomoo
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Minerva Neurosciences Posts 1Q $109.4M Non-Cash Expense For Change in Fair Value of Warrant Liability, Losses Recognized Upon Exercise of Warrants - Moomoo
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):